Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASSIoN trial of intranasal allogeneic mesenchymal stromal cells for neonatal perinatal arterial ischemic stroke
NL-OMON50715Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic bone marrow-derived mesenchymal stromal cells in perinatal arterial ischemic stroke (PAIS), sponsored by University Medical Center Utrecht. Primary endpoints: Acute safety, Dose-limiting toxicity and 1 more. Started Feb 2020; status: completed.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
perinatal arterial ischemic stroke (PAIS)
Beyond the preview
Go deeper on NL-OMON50715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50715.